Key result
Selexipag is recommended as triple oral combination therapy for PAH with insufficient response to dual therapy, but should not replace parenteral prostacyclin in high-risk patients.
Why the study?
Does selexipag improve outcomes in patients with pulmonary arterial hypertension?
Does selexipag improve outcomes in patients with pulmonary arterial hypertension?
Selexipag is a validated oral prostacyclin receptor agonist that should be considered as part of triple oral combination therapy for PAH when response to dual oral therapy is insufficient.
Answers are grounded in this paper and cite their sources.
Supports selexipag addition after dual PAH failure; leaves open need for head-to-head trials versus parenteral prostacyclin.
Introduction : Pulmonary arterial hypertension (PAH) is a rare pulmonary vasculopathy. This review focuses on selexipag, a prostacyclin receptor agonist validated for the treatment of PAH.Areas covered We review the structure, mechanisms of action, pharmacokinetics, and pharmacodynamics of selexipag. Clinical efficacy and tolerability are discussed using the main clinical trial published for selexipag (GRIPHON) and its post-hoc analysis.Expert opinion Selexipag should be added as a triple oral combination therapy in case of insufficient response to oral combination therapy with endothelin receptor antagonist and phosphodiesterase 5 inhibitor. However, selexipag should not replace parenteral prostacyclin in high-risk patients.
No takes yet. Share an insight, caveat, or question.
Genecand et al. (2020) conducted a review in Pulmonary arterial hypertension (PAH). Selexipag was evaluated. Selexipag is recommended as triple oral combination therapy for PAH with insufficient response to dual therapy, but should not replace parenteral prostacyclin in high-risk patients.
Synapse has enriched 10 related papers. Consider them for comparative context: